1-3 of 3
Ian Flinn, M.D.
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Banoxantrone (AQ4N), a Tissue Targeted Prodrug: Results of a Phase 1 Study in Lymphomas.

Richard R. Furman, MD, Nancy L. Bartlett, M.D., Alvin F. Wong, Pharm.D., Leanne M. McCulloch, Pharm.D., Gilbert N. Lam, Ph.D., Todd Rosenthal, Ian Flinn, M.D., John P. Leonard, M.D.
Journal: Blood
Blood (2006) 108 (11): 2429.
https://doi.org/10.1182/blood.V108.11.2429.2429
Published: 2006
Journal Articles

Pharmacokinetics of Single-Agent Lumiliximab (Anti-CD23 Antibody) in Patients with Chronic Lymphocytic Leukemia.

James Woodworth, Ph.D., Bryan R. Leigh, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Aron Thall, Ph.D., Dee Wynne, R.N., John C. Byrd, M.D.
Journal: Blood
Blood (2004) 104 (11): 4831.
https://doi.org/10.1182/blood.V104.11.4831.4831
Published: 2004
Journal Articles

Safety and Efficacy Results from a Phase I Trial of Single-Agent Lumiliximab (Anti-CD23 Antibody) for Chronic Lymphocytic Leukemia.

John C. Byrd, M.D., Susan O’Brien, M.D., Ian Flinn, M.D., Thomas J. Kipps, M.D., Mark A. Weiss, M.D., Kanti Rai, M.D., Thomas S. Lin, M.D., Jennifer Reid, M.S., Dee Wynne, R.N., Bryan R. Leigh, M.D.
Journal: Blood
Blood (2004) 104 (11): 2503.
https://doi.org/10.1182/blood.V104.11.2503.2503
Published: 2004